MAPK3 and neoplasm: Alterations at ERK1/2 level: MEK1/2 are considered the only ERK1/2 activators, and, in that context, a constitutively active ERK mutation would be an effective strategy for tumor cells to bypass the effects of MEK1/2 inhibition.